A Study of XMT-1660 in Participants With Solid Tumors

A Study of XMT-1660 in Participants With Solid Tumors
Conditions:   Triple Negative Breast Cancer;   Breast Cancer;   Endometrial Cancer;   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer
Intervention:   Drug: XMT-1660
Sponsor:   Mersana Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 24, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments